LSD (lysergic acid diethylamide), first synthesized in 1938, is an extremely potent hallucinogen. Hallucinations are when you see, hear, feel, taste, or smell something that seems real but is …

Lysergic acid diethylamide, commonly known as LSD (from German Lysergsäure-diethylamid), is a potent psychedelic drug that intensifies thoughts, emotions, and sensory perception. [11] .

Finally, among the newer antidiabetic drugs that work on the pathophysiological mechanisms shared by T2DM and MASLD, sodium-glucose cotransporter (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) have long been studied.

2024年7月1日 · Successful management of SLD entails accurate diagnosis and disease monitoring through noninvasive methods such as advanced imaging techniques and biomarkers. Many emerging pharmacotherapies for SLD are now in the pipeline, which target different pathways like collagen turnover, fibrogenesis, inflammation, and metabolism.

2024年5月2日 · SIGNIFICANCE STATEMENT: Steatotic liver disease (SLD), including metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis, is the most prevalent chronic liver condition, affecting more than one-fourth of the global population.

2023年10月6日 · Steatotic liver disease (SLD), including metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis, is the most prevalent chronic liver condition, affecting more than one-fourth of the global population.

2024年12月5日 · We introduce the ‘SLD burden paradox’: a concept illustrating the disparity in which metabolic dysfunction-associated steatotic liver disease is more prevalent, yet individuals with SLD and...

The American and European liver associations have endorsed new nomenclature of steatotic liver disease (SLD) and definition of metabolic dysfunction-associated steatotic liver disease (MASLD). To review the historical development leading to the changes and to discuss the implications of the changes on research and clinical practice.

Steatotic liver disease (SLD) is the most common liver disease worldwide and a leading cause of liver-related morbidity and mortality. Current prevalence of SLD is approximately 30 % of the global population with an incidence of 4.6 per 100 patient years [1].

2022年4月11日 · Second-line drug resistance (SLD) among tuberculosis (TB) patients is a serious emerging challenge towards global control of the disease. We characterized SLD-resistance conferring-mutations among TB patients with rifampicin and/or isoniazid (RIF and/or INH) drug-resistance tested at the Uganda National TB Reference Laboratory (NTRL) between ...